Lastly, 55.8% of patients using tapinarof cream 1% in the ADORING 1 trial met the secondary endpoint vs 22.9% in the control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback